title: Comments on Kamimura et al.: significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
authors.affiliation: Department of Metabolism & Endocrinology, The 2nd Xiangya Hospital, Central South University, Renmin road 139#, Changsha, Hunan, 410011, People's Republic of China.|National Clinical Research Center for Metabolic Diseases, The 2nd Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.|Institute of Metabolism and Endocrinology, The 2nd Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.|Department of Endocrinology, Hannan Province Nongken Sanya Hospital, Sanya, Haina, 572000, China.
authors.forename: S J
authors.initials: SJ
authors.lastname: Fu
authors.affiliation: Department of Metabolism & Endocrinology, The 2nd Xiangya Hospital, Central South University, Renmin road 139#, Changsha, Hunan, 410011, People's Republic of China. szf1976@hotmail.com.|National Clinical Research Center for Metabolic Diseases, The 2nd Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. szf1976@hotmail.com.|Institute of Metabolism and Endocrinology, The 2nd Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. szf1976@hotmail.com.
authors.forename: Z F
authors.initials: ZF
authors.lastname: Sheng
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density; D050071:Bone Density Conservation Agents; D016723:Bone Remodeling; D000069448:Denosumab; D004164:Diphosphonates; D006801:Humans; D053245:RANK Ligand
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D000069448:Denosumab